Population Health Assessment
Improve your ability to stratify patient populations based on drug-drug and potential gene-drug interaction risk.
ADEs are a leading cause of quality and cost issues
The ability of healthcare institutions to achieve the quadruple aim is stifled by the negative impact of adverse drug events (ADEs).
1 in 5
$136B
Increase your ability to prevent harmful ADEs
Manage patient populations with precision. Bring an added dimension to your ability to managing medications for large populations while reducing risk.
Stratify large patient populations based on their medication and genetic interaction risk
Identify ideal candidates for pharmacogenetic (PGx) testing
How it works
Identify patients at the highest risk, determine candidates for PGx testing, and proactively manage medications to prevent potentially harmful side effects.
Identify risk and stop drug errors before they happen
Our proprietary genetic prevalence algorithm and custom logic securely ingests large data sets of health information that can risk stratify your patient population.
Get individualized patient reports to view interaction risk, safer therapeutic alternatives, and probability of genetic risk. Work with our expert PharmD and PhD staff to create a customized plan to move patients through PGx testing, manage medication plans, and measure outcomes.
David B. Nash, MD, MBA
Founding Dean Emeritus and the Dr. Raymond C. & Doris Grandon Professor
of Health Policy at Thomas Jefferson University and the Jefferson College of Population Health
